Armelle Vinceneux

445 total citations
28 papers, 263 citations indexed

About

Armelle Vinceneux is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Armelle Vinceneux has authored 28 papers receiving a total of 263 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Armelle Vinceneux's work include Prostate Cancer Treatment and Research (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Renal cell carcinoma treatment (4 papers). Armelle Vinceneux is often cited by papers focused on Prostate Cancer Treatment and Research (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Renal cell carcinoma treatment (4 papers). Armelle Vinceneux collaborates with scholars based in France, United States and Belgium. Armelle Vinceneux's co-authors include Philippe A. Cassier, Mehdi Brahmi, Jean‐Pierre Delord, Aurélien Marabelle, Stéphane Champiat, Nicolas Poirier, Christiane Jungels, B. Vasseur, Nuria Kotecki and Jean‐Baptiste Beauval and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Armelle Vinceneux

26 papers receiving 261 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Armelle Vinceneux France	8	110	103	66	56	32	28	263
Hirotaka Tsuno Japan	7	116 1.1×	58 0.6×	35 0.5×	33 0.6×	65 2.0×	17	273
José Juan Pozo‐Kreilinger Spain	10	82 0.7×	150 1.5×	113 1.7×	30 0.5×	33 1.0×	54	295
Asle C. Hesla Sweden	9	124 1.1×	200 1.9×	72 1.1×	22 0.4×	33 1.0×	14	268
Tifenn Leturcq France	7	123 1.1×	115 1.1×	31 0.5×	66 1.2×	43 1.3×	9	296
Qidang Huang China	10	107 1.0×	21 0.2×	47 0.7×	51 0.9×	102 3.2×	20	262
Jae‐Seung Moon South Korea	8	58 0.5×	32 0.3×	36 0.5×	65 1.2×	52 1.6×	16	208
Kyoo-Ho Shin South Korea	12	99 0.9×	252 2.4×	208 3.2×	42 0.8×	40 1.3×	21	398
Stefan Gerhard Austria	6	117 1.1×	31 0.3×	81 1.2×	15 0.3×	73 2.3×	8	371
Elias Kouchakji United States	6	26 0.2×	205 2.0×	88 1.3×	39 0.7×	84 2.6×	16	358

Countries citing papers authored by Armelle Vinceneux

Since Specialization

Citations

This map shows the geographic impact of Armelle Vinceneux's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Armelle Vinceneux with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Armelle Vinceneux more than expected).

Fields of papers citing papers by Armelle Vinceneux

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Armelle Vinceneux. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Armelle Vinceneux. The network helps show where Armelle Vinceneux may publish in the future.

Co-authorship network of co-authors of Armelle Vinceneux

This figure shows the co-authorship network connecting the top 25 collaborators of Armelle Vinceneux. A scholar is included among the top collaborators of Armelle Vinceneux based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Armelle Vinceneux. Armelle Vinceneux is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chabaud, Sylvie, Aude Fléchon, Helen Boyle, et al.. (2025). Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin. European Journal of Cancer. 222. 115427–115427. 1 indexed citations

Thibault, Constance, Loı̈c Mourey, Dominique Pasquier, et al.. (2025). OCTOPUS: A retrospective, multicenter study of real-world cabozantinib treatment of patients with advanced renal cell carcinoma in France—Subgroup analyses of treatment sequences and optimization.. Journal of Clinical Oncology. 43(5_suppl). 472–472. 1 indexed citations

Corbaux, Pauline, Armelle Vinceneux, Hélène Vanacker, et al.. (2024). Patients’ selection and trial matching in early-phase oncology clinical trials. Critical Reviews in Oncology/Hematology. 196. 104307–104307. 5 indexed citations

Mastroïanni, Bénédicte, Hélène Vanacker, Armelle Vinceneux, et al.. (2024). Qualitative evaluation of motives for acceptance or refusal of early palliative care in patients included in early-phase clinical trials in a French comprehensive cancer center: the PALPHA study. Supportive Care in Cancer. 32(6). 353–353.

Terret, C., Camille Schiffler, Hélène Vanacker, et al.. (2024). Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial. Clinical Cancer Research. 30(10). 2111–2120. 3 indexed citations

Kryza, David, Armelle Vinceneux, Claire Cropet, et al.. (2024). A multicentric, single arm, open-label, phase I/II study evaluating PSMA targeted radionuclide therapy in adult patients with metastatic clear cell renal cancer (PRadR). BMC Cancer. 24(1). 163–163. 10 indexed citations

Dufresne, Armelle, Valéry Attignon, Anthony Ferrari, et al.. (2024). Added value of whole‐exome and RNA sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel. Cancer Medicine. 13(7). e7115–e7115. 1 indexed citations

Stein, Mark N., Laura Graham, Armelle Vinceneux, et al.. (2024). 1659TiP A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer. Annals of Oncology. 35. S1000–S1000. 4 indexed citations

Carneiro, Fátima, Armelle Vinceneux, Mathieu Larroquette, et al.. (2024). Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d′Étude des Tumeurs Uro-Génitales) study. European Journal of Cancer. 199. 113534–113534. 2 indexed citations

10.

Giraudet, Anne‐Laure, Armelle Vinceneux, Jean‐Noël Badel, et al.. (2023). Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma. Pharmaceuticals. 16(7). 995–995. 6 indexed citations

11.

Chvetzoff, Gisèle, Bénédicte Mastroïanni, Hélène Vanacker, et al.. (2022). Reasons for acceptance and refusal of early palliative care in patients included in early-phase clinical trials in a regional comprehensive cancer centre in France: protocol for a qualitative study. BMJ Open. 12(4). e060317–e060317. 2 indexed citations

12.

Vanacker, Hélène, Armelle Vinceneux, Emmanuelle Nicolas‐Virelizier, Mehdi Brahmi, & Philippe A. Cassier. (2021). Anticorps bispécifiques ciblant CD3 en oncologie solide et onco-hématologie. Bulletin du Cancer. 108(10). S181–S194. 3 indexed citations

13.

Champiat, Stéphane, Philippe A. Cassier, Nuria Kotecki, et al.. (2021). Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 2623–2623. 24 indexed citations

14.

Kotecki, Nuria, Stéphane Champiat, J.P. Delord, et al.. (2021). 983P Phase I dose escalation study in patients (pts) with advanced solid tumours receiving first-in-class BI 765063, a selective signal-regulatory protein α (SIRPα) inhibitor, in combination with ezabenlimab (BI 754091), a programmed cell death protein 1 (PD-1) inhibitor. Annals of Oncology. 32. S841–S842. 10 indexed citations

15.

Cattrini, Carlo, Vincenza Conteduca, María Dolores Martínez Ruiz, et al.. (2020). 692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 31. S547–S548. 2 indexed citations

16.

Vinceneux, Armelle, et al.. (2020). Actualités dans le traitement à la rechute des patients atteints de tumeurs germinales. Bulletin du Cancer. 107(9). 912–924. 1 indexed citations

17.

Tresch, Emmanuelle, Jean‐Sébastien Frenel, F. Lerebours, et al.. (2018). 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study. European Journal of Cancer. 95. 30–37. 22 indexed citations

18.

Vinceneux, Armelle, F. Bruyère, O. Haillot, et al.. (2017). Ductal adenocarcinoma of the prostate: Clinical and biological profiles. The Prostate. 77(12). 1242–1250. 24 indexed citations

19.

Lebellec, Loïc, Bruno Chauffert, Jean‐Yves Blay, et al.. (2017). Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). European Journal of Cancer. 79. 119–128. 34 indexed citations

20.

Brahmi, Mehdi, Armelle Vinceneux, & Philippe A. Cassier. (2016). Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis. Current Treatment Options in Oncology. 17(2). 10–10. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact